Merck's Tulisokibart Met Primary and Key Secondary Endpoints in Phase 2b Study in Patients With Moderate to Severe Hidradenitis Suppurativa (HS)
Merck announced positive Phase 2b results for tulisokibart, an anti-TL1A monoclonal antibody, in moderate to severe hidradenitis suppurativa, meeting the primary HiSCR50 endpoint at week 16 in both high- and medium-dose regimens. High-dose patients achieved a 72% HiSCR50 response rate versus 35% on placebo (a 37-point improvement), with medium-dose at 64%; safety was comparable to placebo with no serious or opportunistic infections observed.
Key figures
- Drug Name
- tulisokibart (MK-7240)
- Phase Of Trial
- Phase 2b
- Hiscr50 placebo
- 35%
- Hiscr75 placebo
- 15%
- Hiscr50 low dose
- 52%
- Primary endpoint
- HiSCR50 at week 16
- Hiscr50 high dose
- 72%
- Hiscr75 high dose
- 41%
- Serious ae placebo
- 2.3%
- Hiscr50 medium dose
- 64%
- Hiscr75 medium dose
- 40%
- Serious ae high dose
- 2.4%
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.